Please login to the form below
Cavatek
This page shows the latest Cavatek news and features for those working in and with pharma, biotech and healthcare.
Merck buys cancer-killing virus firm Viralytics for $394m
It will acquire the Australian biotech’s lead cancer therapy Cavatek in the process. ... The pharma group - known as MSD outside the US and Canada - has agreed to buy Australian biotech Viralytics and Cavatek (CVA21), the company’s lead virus-based
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- The UK’s new medicines pricing deal – opportunities and risks for pharma
- Biogen’s Aduhelm unlikely to get approval in Europe
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
